15 November 2018 
EMA/795695/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Yervoy 
ipilimumab 
On 15 November 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Yervoy. The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb Pharma EEIG. 
The CHMP adopted a new indication as follows: 
“Renal Cell Carcinoma (RCC) 
Yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with 
intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).” 
For information, the full indications for Yervoy will be as follows2: 
“Melanoma 
Yervoy as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) 
melanoma in adults, and adolescents 12 years of age and older (see section 4.4). 
Yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or 
metastatic) melanoma in adults. 
Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall 
survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with 
low tumour PD-L1 expression (see sections 4.4 and 5.1). 
Renal Cell Carcinoma (RCC) 
Yervoy in combination with nivolumab is indicated for the first-line treatment of adult 
patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).” 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
Yervoy  
EMA/795695/2018 
Page 2/2 
 
  
  
 
